genedrive plc Cash Flow Conversion Efficiency

Latest as of June 2025: -1.421x

genedrive plc cash flow conversion efficiency. Based on the latest financial reports, genedrive plc (GDR) has a cash flow conversion efficiency ratio of -1.421x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.04 Million ≈ $-248.70 USD) by net assets (GBX1.44 Million ≈ $174.96 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of genedrive plc (2006–2025)

Cash flow conversion efficiency of genedrive plc from 2006 to 2025. This chart illustrates how genedrive plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View genedrive plc stock price for real-time trading data and today's change.

genedrive plc Cash Flow Conversion Ratio Explained

genedrive plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

genedrive plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of genedrive plc ranked by their cash flow conversion efficiency. Also see GDR company net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Cadogan Petroleum plc
LSE:CAD
-0.008x
Red Capital PLC
LSE:REDC
2.418x
MagForce AG
STU:MF6
N/A
Marlowe plc
LSE:MRL
0.184x
Pod Point Group Holdings PLC
LSE:PODP
-1.031x
LANEBURY GROWTH CAP.
F:L01
-0.024x
One Media iP Group Plc
LSE:OMIP
0.048x
FUSION FUEL GREEN CL.A
F:60P
N/A

Annual Cash Flow Conversion Efficiency for genedrive plc (2006–2025)

The table below shows the annual cash flow conversion efficiency of genedrive plc from 2006 to 2025. Review genedrive plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 GBX1.44 Million
≈ $174.96
GBX-5.10 Million
≈ $-620.64
-3.547x -404.51%
2024-06-30 GBX5.36 Million
≈ $652.04
GBX-3.77 Million
≈ $-458.46
-0.703x +62.00%
2023-06-30 GBX2.04 Million
≈ $248.33
GBX-3.78 Million
≈ $-459.43
-1.850x -125.18%
2022-06-30 GBX5.61 Million
≈ $682.70
GBX-4.61 Million
≈ $-560.90
-0.822x +43.07%
2021-06-30 GBX3.59 Million
≈ $437.04
GBX-5.18 Million
≈ $-630.74
-1.443x -227.33%
2020-06-30 GBX-3.34 Million
≈ $-406.62
GBX-3.79 Million
≈ $-460.89
1.133x -22.43%
2019-06-30 GBX-2.48 Million
≈ $-301.50
GBX-3.62 Million
≈ $-440.57
1.461x +39.82%
2018-06-30 GBX-2.44 Million
≈ $-296.51
GBX-2.55 Million
≈ $-309.90
1.045x +295.77%
2017-06-30 GBX3.44 Million
≈ $418.67
GBX-1.84 Million
≈ $-223.51
-0.534x +42.77%
2016-06-30 GBX3.75 Million
≈ $456.63
GBX-3.50 Million
≈ $-425.97
-0.933x -169.33%
2015-06-30 GBX9.54 Million
≈ $1.16K
GBX-3.31 Million
≈ $-402.24
-0.346x -244.58%
2014-06-30 GBX10.86 Million
≈ $1.32K
GBX-1.09 Million
≈ $-132.86
-0.101x -97.99%
2013-06-30 GBX12.05 Million
≈ $1.47K
GBX-612.00K
≈ $-74.46
-0.051x -66.01%
2012-06-30 GBX8.86 Million
≈ $1.08K
GBX-271.00K
≈ $-32.97
-0.031x +72.95%
2011-06-30 GBX6.18 Million
≈ $752.17
GBX-699.00K
≈ $-85.05
-0.113x +8.53%
2010-06-30 GBX5.78 Million
≈ $703.75
GBX-715.00K
≈ $-86.99
-0.124x -118.01%
2009-06-30 GBX2.76 Million
≈ $335.81
GBX1.89 Million
≈ $230.45
0.686x +256.66%
2008-06-30 GBX2.58 Million
≈ $314.15
GBX-1.13 Million
≈ $-137.61
-0.438x -41.49%
2007-06-30 GBX2.60 Million
≈ $315.98
GBX-804.00K
≈ $-97.82
-0.310x +61.17%
2006-06-30 GBX1.09 Million
≈ $133.23
GBX-873.00K
≈ $-106.22
-0.797x --

About genedrive plc

LSE:GDR UK Diagnostics & Research
Market Cap
$122.14K
GBX1.00 Billion GBX
Market Cap Rank
#31476 Global
#1082 in UK
Share Price
GBX0.98
Change (1 day)
+0.00%
52-Week Range
GBX0.74 - GBX1.40
All Time High
GBX217.89
About

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more